HCV Protease

Choose Selective HCV Protease Inhibitors

HCV Protease Signaling Pathway Map

HCV Protease Signaling Pathways

HCV Protease Products

  • All (23)
  • HCV Protease Inhibitors (23)
  • New HCV Protease Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1183 Danoprevir (ITMN-191) Danoprevir (ITMN-191, RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
J Cell Biochem, 2022, 10.1002/jcb.30213
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
S1480 Lomibuvir (VX-222) Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.
J Virol, 2022, jvi0190621
Sci Rep, 2021, 11(1):19443
Antimicrob Agents Chemother, 2019, 63(6)
S1482 Daclatasvir (BMS-790052) Daclatasvir (BMS-790052, EBP883) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
Commun Biol, 2022, 5(1):154
Med Mol Morphol, 2021, 10.1007/s00795-020-00271-5
bioRxiv, 2021, 2021.07.21.453274
S1538 Telaprevir (VX-950) Telaprevir (VX-950, LY-570310, MP-424) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
J Cell Biochem, 2022, 10.1002/jcb.30213
Cell Rep, 2021, 35(7):109133
Front Pharmacol, 2021, 12:773198
S2074 Mecarbinate Mecarbinate (Dimecarbin) is a chemical intermediate of arbidol hydrochloride.
S2794 Sofosbuvir (GS-7977) Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Nat Commun, 2022, 13(1):2079
Front Oncol, 2021, 11:803278
Int J Mol Sci, 2021, 22(9)4559
S3395 Tegobuvir Tegobuvir (TGV, GS 333126, GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients.
S3724 Velpatasvir Velpatasvir (GS-5816) is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
Front Oncol, 2021, 11:803278
Drug Metab Dispos, 2020, 48(12):1264-1270
Front Microbiol, 2020, 10:2936
S3728 Grazoprevir Grazoprevir anhydrous (MK5172) is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.
Cell Rep, 2021, 35(7):109133
Front Oncol, 2021, 11:803278
Sci Rep, 2021, 11(1):19443
S3733 Boceprevir Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
J Cell Biochem, 2022, 10.1002/jcb.30213
Cell Rep, 2021, 35(7):109133
Front Pharmacol, 2021, 12:773198
S3800 Lycorine hydrochloride Lycorine (Galanthidine, Amarylline, Narcissine, Licorine), a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity.
Aging Cell, 2021, e13307
S4935 Asunaprevir (BMS-650032) Asunaprevir (BMS-650032) is an orally bioavailable inhibitor of the hepatitis C virus enzyme serine protease NS3 that is necessary for protein processing required for viral replication.
Cell Rep, 2021, 35(7):109133
bioRxiv, 2021, 10.1101/2021.07.16.452672
Viruses, 2021, 13(2)173
S5015 Simeprevir (TMC435) Simeprevir (TMC-435, TMC-435350) is a competitive, reversible, macrocyclic, noncovalent hepatitis C virus (HCV) NS3/4A protease inhibitor that acts directly against the hepatitis C virus. It has a medium inhibitory concentration (IC50) <13 nM for all HCV NS3/4A enzymes(genotypes 1a, 1b, 2, 4, 5, and 6), but has an IC50 value of 37 nM for genotype 3.
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
Viruses, 2021, 13(2)173
S5062 Daclatasvir Dihydrochloride Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.
Commun Biol, 2022, 5(1):154
J Antimicrob Chemother, 2021, 76(7):1874-1885
Med Mol Morphol, 2021, 10.1007/s00795-020-00271-5
S5307 PSI-6206 (GS-331007) PSI-6206 (RO-2433, GS-331007) is a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase, targeting NS5B polymerase.
S5394 Tizoxanide Tizoxanide (Desacetyl-nitazoxanide), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.
S5402 Dasabuvir (ABT-333) Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.
Sci Rep, 2021, 11(1):19443
S5403 Ombitasvir (ABT-267) Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.
Commun Biol, 2022, 5(1):154
Sci Rep, 2021, 11(1):19443
bioRxiv, 2021, 2021.07.21.453274
S5404 Paritaprevir (ABT-450) Paritaprevir (ABT-450) is a nonstructural (NS) protein 3/4A protease inhibitor.
Cell Rep, 2021, 35(7):109133
S5652 Elbasvir Elbasvir (MK8742) is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype.
S5720 Glecaprevir Glecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
S7579 Ledipasvir (GS5885) Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Sci Rep, 2021, 11(1):19443
Cancers (Basel), 2019, 11(10)E1407
Biol Pharm Bull, 2019, 10.1248/bpb.b19-00641
S9641 Pibrentasvir (ABT-530) Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
S1183 Danoprevir (ITMN-191) Danoprevir (ITMN-191, RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
J Cell Biochem, 2022, 10.1002/jcb.30213
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
S1480 Lomibuvir (VX-222) Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.
J Virol, 2022, jvi0190621
Sci Rep, 2021, 11(1):19443
Antimicrob Agents Chemother, 2019, 63(6)
S1482 Daclatasvir (BMS-790052) Daclatasvir (BMS-790052, EBP883) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
Commun Biol, 2022, 5(1):154
Med Mol Morphol, 2021, 10.1007/s00795-020-00271-5
bioRxiv, 2021, 2021.07.21.453274
S1538 Telaprevir (VX-950) Telaprevir (VX-950, LY-570310, MP-424) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
J Cell Biochem, 2022, 10.1002/jcb.30213
Cell Rep, 2021, 35(7):109133
Front Pharmacol, 2021, 12:773198
S2074 Mecarbinate Mecarbinate (Dimecarbin) is a chemical intermediate of arbidol hydrochloride.
S2794 Sofosbuvir (GS-7977) Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Nat Commun, 2022, 13(1):2079
Front Oncol, 2021, 11:803278
Int J Mol Sci, 2021, 22(9)4559
S3395 Tegobuvir Tegobuvir (TGV, GS 333126, GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients.
S3724 Velpatasvir Velpatasvir (GS-5816) is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
Front Oncol, 2021, 11:803278
Drug Metab Dispos, 2020, 48(12):1264-1270
Front Microbiol, 2020, 10:2936
S3728 Grazoprevir Grazoprevir anhydrous (MK5172) is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.
Cell Rep, 2021, 35(7):109133
Front Oncol, 2021, 11:803278
Sci Rep, 2021, 11(1):19443
S3733 Boceprevir Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
J Cell Biochem, 2022, 10.1002/jcb.30213
Cell Rep, 2021, 35(7):109133
Front Pharmacol, 2021, 12:773198
S3800 Lycorine hydrochloride Lycorine (Galanthidine, Amarylline, Narcissine, Licorine), a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity.
Aging Cell, 2021, e13307
S4935 Asunaprevir (BMS-650032) Asunaprevir (BMS-650032) is an orally bioavailable inhibitor of the hepatitis C virus enzyme serine protease NS3 that is necessary for protein processing required for viral replication.
Cell Rep, 2021, 35(7):109133
bioRxiv, 2021, 10.1101/2021.07.16.452672
Viruses, 2021, 13(2)173
S5015 Simeprevir (TMC435) Simeprevir (TMC-435, TMC-435350) is a competitive, reversible, macrocyclic, noncovalent hepatitis C virus (HCV) NS3/4A protease inhibitor that acts directly against the hepatitis C virus. It has a medium inhibitory concentration (IC50) <13 nM for all HCV NS3/4A enzymes(genotypes 1a, 1b, 2, 4, 5, and 6), but has an IC50 value of 37 nM for genotype 3.
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
Viruses, 2021, 13(2)173
S5062 Daclatasvir Dihydrochloride Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.
Commun Biol, 2022, 5(1):154
J Antimicrob Chemother, 2021, 76(7):1874-1885
Med Mol Morphol, 2021, 10.1007/s00795-020-00271-5
S5307 PSI-6206 (GS-331007) PSI-6206 (RO-2433, GS-331007) is a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase, targeting NS5B polymerase.
S5394 Tizoxanide Tizoxanide (Desacetyl-nitazoxanide), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.
S5402 Dasabuvir (ABT-333) Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.
Sci Rep, 2021, 11(1):19443
S5403 Ombitasvir (ABT-267) Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.
Commun Biol, 2022, 5(1):154
Sci Rep, 2021, 11(1):19443
bioRxiv, 2021, 2021.07.21.453274
S5404 Paritaprevir (ABT-450) Paritaprevir (ABT-450) is a nonstructural (NS) protein 3/4A protease inhibitor.
Cell Rep, 2021, 35(7):109133
S5652 Elbasvir Elbasvir (MK8742) is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype.
S5720 Glecaprevir Glecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
S7579 Ledipasvir (GS5885) Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Sci Rep, 2021, 11(1):19443
Cancers (Basel), 2019, 11(10)E1407
Biol Pharm Bull, 2019, 10.1248/bpb.b19-00641
S9641 Pibrentasvir (ABT-530) Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
Tags: HCV protease treatment | HCV protease assay | HCV protease inhibitors review